Ed Tate

Ed Tate is a Professor and GSK Chair in Chemical Biology at Imperial College London's Department of Chemistry, part of the Faculty of Natural Sciences. He also holds a Satellite Group Leader position at the Francis Crick Institute. His research bridges organic chemistry, life sciences, and medicine, focusing on chemical biology and proteomics to understand disease mechanisms. He has pioneered methods for protein manipulation and drug discovery, including work on CD59 inhibitors and N-myristoyltransferase (NMT) inhibitors for malaria and cancer.

Education: B.Sc. in Chemistry (University of Durham), Ph.D. in Organic Chemistry (University of Cambridge) under Prof. Steve Ley. Postdoctoral training included radical chemistry at École Polytechnique and molecular microbiology at the Pasteur Institute. Career progression: Senior Lecturer (2010), Reader (2012), Professor (2014), GSK Chair (2023).

Research interests include chemical proteomics, targeted protein degradation, drug development, and understanding post-translational modifications like ADP-ribosylation and S-palmitoylation. His lab has spun out Myricx Bio, a biotech company developing antibody-drug conjugates.

Awards include the 2020 RSC Corday-Morgan Prize, 2019 Sir David Cooksey Translation Prize, and multiple fellowships. Grants include funding from UK research councils, charities, and industry partnerships.

Labs/Teams: Tate Group at Imperial and Francis Crick Institute, leading the Centre for Drug Discovery Science. Active in editorial roles for journals like Cell Chemical Biology and advisory roles for biopharma companies.